|
US563536A
(en)
|
|
1896-07-07 |
|
Bracket for swinging stages |
|
US914623A
(en)
|
1908-08-19 |
1909-03-09 |
Henry H Williams |
Process in the manufacture of generating-plates for x-ray machines.
|
|
US1051266A
(en)
|
1910-09-26 |
1913-01-21 |
George I Rockwood |
Apparatus for operating alarms or other devices.
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4897445A
(en)
|
1986-06-27 |
1990-01-30 |
The Administrators Of The Tulane Educational Fund |
Method for synthesizing a peptide containing a non-peptide bond
|
|
WO1995024221A1
(en)
|
1986-08-18 |
1995-09-14 |
The Dow Chemical Company |
Bioactive and/or targeted dendrimer conjugates
|
|
ATE87659T1
(de)
|
1986-09-02 |
1993-04-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
DE3642912A1
(de)
|
1986-12-16 |
1988-06-30 |
Leybold Ag |
Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
CA1341245C
(en)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Recombinant vaccinia virus mva
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US5744166A
(en)
|
1989-02-25 |
1998-04-28 |
Danbiosyst Uk Limited |
Drug delivery compositions
|
|
US5100587A
(en)
|
1989-11-13 |
1992-03-31 |
The United States Of America As Represented By The Department Of Energy |
Solid-state radioluminescent zeolite-containing composition and light sources
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5179993A
(en)
|
1991-03-26 |
1993-01-19 |
Hughes Aircraft Company |
Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
|
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
|
US5976551A
(en)
|
1991-11-15 |
1999-11-02 |
Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and method of using the determinant
|
|
US5734023A
(en)
|
1991-11-19 |
1998-03-31 |
Anergen Inc. |
MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
US5747323A
(en)
|
1992-12-31 |
1998-05-05 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Retroviral vectors comprising a VL30-derived psi region
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
FR2707091B1
(fr)
|
1993-06-30 |
1997-04-04 |
Cohen Haguenauer Odile |
Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
|
|
US5820866A
(en)
|
1994-03-04 |
1998-10-13 |
National Jewish Center For Immunology And Respiratory Medicine |
Product and process for T cell regulation
|
|
FR2719316B1
(fr)
|
1994-04-28 |
1996-05-31 |
Idm |
Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
|
|
JP3816518B2
(ja)
|
1994-06-10 |
2006-08-30 |
ジェンベク、インコーポレイティッド |
相補的なアデノウイルスベクター系と細胞系
|
|
US5851806A
(en)
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
|
WO1996000295A1
(en)
|
1994-06-27 |
1996-01-04 |
The Johns Hopkins University |
Targeted gene delivery system
|
|
FR2722506B1
(fr)
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
|
US7074904B2
(en)
|
1994-07-29 |
2006-07-11 |
Altor Bioscience Corporation |
MHC complexes and uses thereof
|
|
US5965541A
(en)
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
|
US5559099A
(en)
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
|
CA2206915A1
(en)
|
1994-12-21 |
1996-06-27 |
Konstantinos Skobridis |
Oligonucleotide-dendrimer conjugates
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
DE69634084T2
(de)
|
1995-06-07 |
2005-12-08 |
Inex Pharmaceuticals Corp. |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
DE69638058D1
(de)
|
1995-06-15 |
2009-11-26 |
Crucell Holland Bv |
Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
US5837511A
(en)
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
WO1997035996A1
(en)
|
1996-03-25 |
1997-10-02 |
Transgene S.A. |
Packaging cell line based on human 293 cells
|
|
CA2177085C
(en)
|
1996-04-26 |
2007-08-14 |
National Research Council Of Canada |
Adenovirus e1-complementing cell lines
|
|
CA2258158A1
(fr)
|
1996-07-01 |
1998-01-08 |
Francis Blanche |
Procede de production d'adenovirus recombinants
|
|
EP0920339A2
(en)
|
1996-07-09 |
1999-06-09 |
The Johns Hopkins University |
Gene delivery system
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
ES2349046T3
(es)
|
1996-12-13 |
2010-12-22 |
Schering Corporation |
Métodos para purificar virus.
|
|
FR2759382A1
(fr)
|
1997-02-10 |
1998-08-14 |
Transgene Sa |
Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
|
|
FR2760193B1
(fr)
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
|
|
JP2000509614A
(ja)
|
1997-03-04 |
2000-08-02 |
バクスター インターナショナル インコーポレイテッド |
アデノウイルスｅ１−相補性細胞系
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
US6020191A
(en)
|
1997-04-14 |
2000-02-01 |
Genzyme Corporation |
Adenoviral vectors capable of facilitating increased persistence of transgene expression
|
|
ES2301198T3
(es)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
Polipeptidos artificiales de anticuerpos.
|
|
US6207195B1
(en)
|
1997-06-13 |
2001-03-27 |
The Johns Hopkins University |
Therapeutic nanospheres
|
|
US6270772B1
(en)
|
1997-09-16 |
2001-08-07 |
Oregon Health Sciences University |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6232445B1
(en)
|
1997-10-29 |
2001-05-15 |
Sunol Molecular Corporation |
Soluble MHC complexes and methods of use thereof
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US6113913A
(en)
|
1998-06-26 |
2000-09-05 |
Genvec, Inc. |
Recombinant adenovirus
|
|
US6440442B1
(en)
|
1998-06-29 |
2002-08-27 |
Hydromer, Inc. |
Hydrophilic polymer blends used for dry cow therapy
|
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
|
DE60029195T2
(de)
|
1999-02-22 |
2007-06-28 |
Transgene S.A. |
Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
|
|
AU777041B2
(en)
|
1999-05-17 |
2004-09-30 |
Crucell Holland B.V. |
Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
|
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
DE60038971D1
(de)
|
1999-10-22 |
2008-07-03 |
Aventis Pasteur |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
US20030198953A1
(en)
|
2000-03-30 |
2003-10-23 |
Spytek Kimberly A. |
Novel proteins and nucleic acids encoding same
|
|
US20020192763A1
(en)
*
|
2000-04-17 |
2002-12-19 |
Jiangchun Xu |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
NZ524661A
(en)
|
2000-11-23 |
2005-03-24 |
Bavarian Nordic As |
Modified vaccinia ankara virus variant
|
|
AU3942202A
(en)
|
2000-11-30 |
2002-06-11 |
Medarex Inc |
Transgenic transchromosomal rodents for making human antibodies
|
|
US20150329617A1
(en)
|
2001-03-14 |
2015-11-19 |
Dynal Biotech Asa |
Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
PL208712B1
(pl)
|
2001-08-31 |
2011-05-31 |
Avidex Ltd |
Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
|
|
JP2005519606A
(ja)
*
|
2002-03-14 |
2005-07-07 |
エグゾニ・テラピューティック・ソシエテ・アノニム |
ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
|
|
PT1420822E
(pt)
|
2002-04-19 |
2007-09-04 |
Bavarian Nordic As |
Vírus vacínia modificado ancara para a vacinação de neonatais
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
WO2004033685A1
(en)
|
2002-10-09 |
2004-04-22 |
Avidex Ltd |
Single chain recombinant t cell receptors
|
|
MXPA05005051A
(es)
|
2002-11-12 |
2006-03-10 |
Albert B Deisseroth |
Vacuna de vector adenoviral.
|
|
US7638134B2
(en)
|
2003-02-20 |
2009-12-29 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Insertion sites in fowlpox vectors
|
|
WO2004113571A2
(en)
|
2003-06-26 |
2004-12-29 |
Exonhit Therapeutics Sa |
Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
|
|
EP3144011A1
(en)
|
2003-09-05 |
2017-03-22 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
GB2408507B
(en)
|
2003-10-06 |
2005-12-14 |
Proimmune Ltd |
Chimeric MHC protein and oligomer thereof for specific targeting
|
|
EP1687033A4
(en)
|
2003-11-12 |
2008-06-11 |
Us Navy |
STRENGTHENING IMMUNE RESPONSE INDUCED BY A VACCINE AND HETEROLOGOUS AMPLIFICATION PROTECTION WITH ALPHAVIRUS REPLICON VACCINES
|
|
US8299229B2
(en)
|
2003-11-24 |
2012-10-30 |
Microvax, Llc |
Mucin antigen vaccine
|
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
|
CN107723298A
(zh)
|
2004-01-23 |
2018-02-23 |
Msd意大利有限公司 |
黑猩猩腺病毒疫苗载运体
|
|
WO2006056766A2
(en)
|
2004-11-24 |
2006-06-01 |
St George's Enterprises Limited |
Diagnosis of prostate cancer
|
|
EP1683808A1
(en)
|
2005-01-25 |
2006-07-26 |
Het Nederlands Kanker Instituut |
Means and methods for breaking noncovalent binding interactions between molecules
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
US20100143302A1
(en)
|
2006-03-16 |
2010-06-10 |
Crucell Holland B.V. |
Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
|
|
AR060070A1
(es)
|
2006-03-24 |
2008-05-21 |
Merck Patent Gmbh |
Dominios proteicos heterodimericos obtenidos por ingenieria
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
EP1878744A1
(en)
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
|
|
GB2442048B
(en)
|
2006-07-25 |
2009-09-30 |
Proimmune Ltd |
Biotinylated MHC complexes and their uses
|
|
GB2440529B
(en)
|
2006-08-03 |
2009-05-13 |
Proimmune Ltd |
MHC Oligomer, Components Therof, And Methods Of Making The Same
|
|
US7910565B2
(en)
|
2006-09-01 |
2011-03-22 |
Wisconsin Alumni Research Foundation |
Prostate cancer vaccine
|
|
ES2500465T3
(es)
|
2006-10-06 |
2014-09-30 |
Bavarian Nordic Inc. |
Virus vaccinia Ankara modificado recombinante que codifica antígeno HER-2 en combinación con un taxano para uso en el tratamiento del cáncer
|
|
WO2008106615A1
(en)
|
2007-02-28 |
2008-09-04 |
Numenta, Inc. |
Spatio-temporal learning algorithms in hierarchical temporal networks
|
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
|
DK2207564T3
(en)
|
2007-10-18 |
2017-01-16 |
Bavarian Nordic As |
USE OF VAT FOR TREATMENT OF PROSTATACANCES
|
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
ES2567564T3
(es)
|
2007-11-19 |
2016-04-25 |
Transgene Sa |
Vectores oncolíticos de poxvirus
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
PL2235064T3
(pl)
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
|
US10131921B2
(en)
|
2008-03-06 |
2018-11-20 |
Mayo Foundation For Medical Education And Research |
Single cycle replicating adenovirus vectors
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
EP3062106B1
(en)
|
2008-04-16 |
2020-11-11 |
The Johns Hopkins University |
Method for determining androgen receptor variants in prostate cancer
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX359574B
(es)
|
2008-09-03 |
2018-10-03 |
Univ Johns Hopkins |
Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
WO2010045340A1
(en)
|
2008-10-14 |
2010-04-22 |
Centocor Ortho Biotech Inc. |
Methods of humanizing and affinity-maturing antibodies
|
|
US8278419B2
(en)
|
2008-10-31 |
2012-10-02 |
Centocor Ortho Biotech Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
|
EP2774985B1
(en)
|
2008-10-31 |
2016-12-14 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus SAdV-43 and uses thereof
|
|
CN102639709A
(zh)
|
2009-01-09 |
2012-08-15 |
密歇根大学董事会 |
癌症中的复现性基因融合体
|
|
KR101763093B1
(ko)
|
2009-02-02 |
2017-07-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
|
|
DK2396011T3
(en)
|
2009-02-12 |
2016-04-25 |
Janssen Biotech Inc |
Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
|
|
US8394385B2
(en)
|
2009-03-13 |
2013-03-12 |
Bavarian Nordic A/S |
Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
|
|
ES2708124T3
(es)
|
2009-04-27 |
2019-04-08 |
Oncomed Pharm Inc |
Procedimiento para preparar moléculas heteromultiméricas
|
|
WO2010132867A1
(en)
|
2009-05-15 |
2010-11-18 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy
|
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
|
PT3338765T
(pt)
|
2009-12-01 |
2019-03-18 |
Translate Bio Inc |
Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
|
|
GB201002730D0
(en)
|
2010-02-18 |
2010-04-07 |
Uni I Oslo |
Product
|
|
RU2612788C2
(ru)
|
2010-03-23 |
2017-03-13 |
Интрексон Корпорейшн |
Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
|
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
US20170039314A1
(en)
|
2010-03-23 |
2017-02-09 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
WO2011131746A2
(en)
|
2010-04-20 |
2011-10-27 |
Genmab A/S |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
EP2590670B1
(en)
|
2010-07-06 |
2017-08-23 |
GlaxoSmithKline Biologicals SA |
Methods of raising an immune response by delivery of rna
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のｒｎａを用いた大型哺乳動物の免疫化
|
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
|
WO2012006376A2
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Virion-like delivery particles for self-replicating rna molecules
|
|
EP2420253A1
(en)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
|
RS63984B1
(sr)
|
2010-08-31 |
2023-03-31 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
HRP20220695T1
(hr)
|
2010-08-31 |
2022-07-08 |
Glaxosmithkline Biologicals Sa |
Pegilirani liposomi za isporuku rnk kodirane za imunogen
|
|
EP2621523B1
(en)
|
2010-09-29 |
2017-08-09 |
UTI Limited Partnership |
Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
|
|
US10023657B2
(en)
|
2010-10-01 |
2018-07-17 |
Ludwig Institute For Cancer Research Ltd. |
Reversible protein multimers, methods for their production and use
|
|
EP2635607B1
(en)
|
2010-11-05 |
2019-09-04 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
EP2502934B1
(en)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
|
|
WO2012149522A1
(en)
|
2011-04-28 |
2012-11-01 |
Baylor College Of Medicine |
Recurrent chimeric rnas enriched in human prostate cancer as biomarkers
|
|
GB201108879D0
(en)
|
2011-05-25 |
2011-07-06 |
Isis Innovation |
Vector
|
|
US9132281B2
(en)
|
2011-06-21 |
2015-09-15 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
|
RU2014104090A
(ru)
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
ES2705498T3
(es)
|
2011-08-31 |
2019-03-25 |
Glaxosmithkline Biologicals Sa |
Liposomas pegilados para administración de ARN que codifica inmunógeno
|
|
JP6757121B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
|
|
EP2768530A1
(en)
|
2011-10-11 |
2014-08-27 |
Novartis AG |
Recombinant self-replicating polycistronic rna molecules
|
|
SI2771364T1
(sl)
|
2011-10-27 |
2019-10-30 |
Genmab As |
Produkcija heterodimernih proteinov
|
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス，インコーポレイテッド |
Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
|
CA2859667C
(en)
|
2011-12-20 |
2022-05-24 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
|
CA2863523A1
(en)
|
2012-02-02 |
2013-08-08 |
Juan FUEYO-MARGARETO |
Recombinant adenovirus expressing cancer antigens
|
|
US20160078168A1
(en)
|
2012-02-13 |
2016-03-17 |
Splicingcodes.Com |
Fusion transcript detection methods and fusion transcripts identified thereby
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
AU2013243946A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
|
CN114163530A
(zh)
|
2012-04-20 |
2022-03-11 |
美勒斯公司 |
用于产生免疫球蛋白样分子的方法和手段
|
|
DE202013012242U1
(de)
*
|
2012-05-25 |
2016-02-02 |
Emmanuelle Charpentier |
Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
|
|
JP2015523412A
(ja)
|
2012-07-30 |
2015-08-13 |
ワウ ヒン イェウング，アレックス |
腫瘍細胞、ＧＭ‐ＣＳＦのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも２種または全３種の同時投与により作られる生のｉｎｖｉｖｏ腫瘍特異的がんワクチンシステム
|
|
US10973892B2
(en)
|
2012-09-04 |
2021-04-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
|
US10155031B2
(en)
|
2012-11-28 |
2018-12-18 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
CA2897858A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
NZ715815A
(en)
|
2013-06-26 |
2017-02-24 |
Guangzhou Xiangxue Pharmaceutical Co Ltd |
High-stability t-cell receptor and preparation method and application thereof
|
|
US10350275B2
(en)
|
2013-09-21 |
2019-07-16 |
Advantagene, Inc. |
Methods of cytotoxic gene therapy to treat tumors
|
|
EP3412304A3
(en)
|
2013-10-23 |
2019-03-20 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
|
|
RU2714142C2
(ru)
|
2013-11-05 |
2020-02-12 |
Бавариан Нордик А/С |
Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
|
|
AU2014346852A1
(en)
|
2013-11-05 |
2016-06-16 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
AU2014348212C1
(en)
|
2013-11-18 |
2018-11-29 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
SG10201907841UA
(en)
|
2013-11-22 |
2019-10-30 |
Dnatrix Inc |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
SI3074517T1
(sl)
|
2013-11-28 |
2021-12-31 |
Bavarian Nordic A/S |
Sestavki in postopki za spodbujanje izboljšanega imunskega odziva z uporabo vektorjev poksvirusa
|
|
US20170106065A1
(en)
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
|
US9884075B2
(en)
|
2014-01-16 |
2018-02-06 |
California Institute Of Technology |
Domain-swap T cell receptors
|
|
EP3542816A1
(en)
|
2014-02-14 |
2019-09-25 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
|
WO2015128421A1
(en)
|
2014-02-28 |
2015-09-03 |
Crucell Holland B.V. |
Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
|
|
EP3119426A4
(en)
|
2014-03-19 |
2018-02-28 |
Mayo Foundation for Medical Education and Research |
Methods and materials for treating cancer
|
|
EP3981437A1
(en)
|
2014-04-23 |
2022-04-13 |
ModernaTX, Inc. |
Nucleic acid vaccines
|
|
ES2851451T3
(es)
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
|
IL248507B
(en)
|
2014-05-13 |
2022-07-01 |
Bavarian Nordic As |
Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule
|
|
KR20170003692A
(ko)
|
2014-05-15 |
2017-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
|
|
WO2015192068A1
(en)
|
2014-06-12 |
2015-12-17 |
The Johns Hopkins University |
Combinatorial immunotherapy for pancreatic cancer treatment
|
|
US10512684B2
(en)
|
2014-09-26 |
2019-12-24 |
Bavarian Nordic A/S |
Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
|
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
|
CN107949397A
(zh)
|
2015-02-13 |
2018-04-20 |
特兰斯吉恩股份有限公司 |
免疫治疗疫苗和抗体组合治疗
|
|
EP3283088A4
(en)
|
2015-04-17 |
2018-10-24 |
Memorial Sloan-Kettering Cancer Center |
Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
|
|
GB201506642D0
(en)
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
|
DK3326641T3
(da)
|
2015-04-22 |
2019-09-30 |
Curevac Ag |
Rna-holdig sammensætning til behandling af tumorsygdomme
|
|
CN108513593A
(zh)
|
2015-04-23 |
2018-09-07 |
南托米克斯有限责任公司 |
癌症新表位
|
|
CA2984485A1
(en)
|
2015-05-06 |
2016-12-15 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
|
CN107810009A
(zh)
|
2015-05-15 |
2018-03-16 |
库瑞瓦格股份公司 |
涉及施用至少一种mRNA构建体的初免‑加强方案
|
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
|
US10481158B2
(en)
|
2015-06-01 |
2019-11-19 |
California Institute Of Technology |
Compositions and methods for screening T cells with antigens for specific populations
|
|
US10995140B2
(en)
|
2015-06-05 |
2021-05-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
|
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
|
WO2017015064A1
(en)
|
2015-07-20 |
2017-01-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Detection phenotyping and quantitation of cells with multimeric binding reagent
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
WO2017020026A1
(en)
*
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
SG10202001501QA
(en)
|
2015-08-20 |
2020-04-29 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv18 vaccines
|
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
CN108430456B
(zh)
|
2015-10-22 |
2022-01-18 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2017075440A1
(en)
|
2015-10-30 |
2017-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Targeted cancer therapy
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
CA3005482A1
(en)
|
2015-12-02 |
2017-06-08 |
Innovative Targeting Solutions Inc. |
Single variable domain t-cell receptors
|
|
SG11201807022XA
(en)
|
2016-02-25 |
2018-09-27 |
Memorial Sloan Kettering Cancer Center |
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
WO2017152042A2
(en)
|
2016-03-04 |
2017-09-08 |
New York University |
Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
MA44524A
(fr)
|
2016-03-31 |
2019-02-06 |
Neon Therapeutics Inc |
Néoantigènes et leurs procédés d'utilisation
|
|
CA3056212A1
(en)
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
EP4186518A1
(en)
|
2016-05-18 |
2023-05-31 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109476718B
(zh)
|
2016-05-18 |
2023-07-04 |
莫得纳特斯公司 |
编码免疫调节多肽的mrna的组合及其用途
|
|
US20200282032A1
(en)
|
2016-05-27 |
2020-09-10 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
|
JP7184337B2
(ja)
|
2016-06-14 |
2022-12-06 |
ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
|
|
MX2018015540A
(es)
|
2016-06-20 |
2019-04-11 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
|
US20190185859A1
(en)
|
2016-08-19 |
2019-06-20 |
Curevac Ag |
Rna for cancer therapy
|
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
US10307477B2
(en)
|
2016-09-02 |
2019-06-04 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
PL3293201T3
(pl)
|
2016-09-12 |
2021-06-14 |
Targovax Oy |
Łączenie adenowirusa i inhibitorów punktów kontrolnych do leczenia nowotworu
|
|
RU2756534C2
(ru)
|
2016-09-28 |
2021-10-01 |
Бавариан Нордик А/С |
Композиции и способы для повышения стабильности трансгенов в поксвирусах
|
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
|
JP7382230B2
(ja)
|
2016-10-17 |
2023-11-16 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組み換えウイルスレプリコン系及びその使用
|
|
JP2020500847A
(ja)
|
2016-11-16 |
2020-01-16 |
プライムヴァックス イミュノ−オンコロジー，インク． |
癌の処置のための併用免疫療法
|
|
MX2019006010A
(es)
|
2016-11-23 |
2019-12-05 |
Gritstone Oncology Inc |
Administracion viral de neoantigenos.
|
|
WO2018102585A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
|
|
AU2017367642A1
(en)
|
2016-11-30 |
2019-05-30 |
Advaxis, Inc. |
Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
|
|
KR102655641B1
(ko)
|
2016-12-05 |
2024-04-05 |
얀센 파마슈티칼즈, 인코포레이티드 |
유전자 발현을 향상시키기 위한 조성물 및 방법
|
|
WO2018107011A1
(en)
|
2016-12-08 |
2018-06-14 |
City Of Hope |
P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
|
|
US10459372B2
(en)
|
2017-01-31 |
2019-10-29 |
Hewlett-Packard Development Company, L.P. |
Binary ink developer (BID) assembly for liquid electrophotography (LEP) printing device
|
|
AU2017397458A1
(en)
|
2017-02-01 |
2019-08-15 |
Modernatx, Inc. |
RNA cancer vaccines
|
|
US11229668B2
(en)
|
2017-02-07 |
2022-01-25 |
Nantcell, Inc. |
Maximizing T-cell memory and compositions and methods therefor
|
|
CN110268061A
(zh)
|
2017-02-09 |
2019-09-20 |
扬森疫苗与预防公司 |
用于表达异源基因的有效的短启动子
|
|
CN110582578B
(zh)
|
2017-02-10 |
2024-02-02 |
洛克菲勒大学 |
用于细胞类型特异性谱分析以鉴定药物靶标的方法
|
|
EP3589312A1
(en)
|
2017-03-03 |
2020-01-08 |
New York University |
Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
US20230241207A1
(en)
|
2017-04-03 |
2023-08-03 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
|
WO2018194890A1
(en)
|
2017-04-19 |
2018-10-25 |
University Of Iowa Research Foundation |
Cancer vaccines and methods of producing and using same
|
|
TW202333779A
(zh)
|
2017-05-08 |
2023-09-01 |
美商磨石生物公司 |
阿爾法病毒新抗原載體
|
|
WO2018209315A1
(en)
|
2017-05-12 |
2018-11-15 |
Memorial Sloan Kettering Cancer Center |
Vaccinia virus mutants useful for cancer immunotherapy
|
|
JP2020522477A
(ja)
|
2017-06-02 |
2020-07-30 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
汎用癌ワクチンおよびそれを製造ならびに使用する方法
|
|
JP7334124B2
(ja)
|
2017-06-21 |
2023-08-28 |
トランジェーヌ |
個別化ワクチン
|
|
BR112020000145A2
(pt)
|
2017-07-05 |
2020-07-14 |
Nouscom Ag |
polinucleotídeos, adenovírus isolado, partícula semelhante a vírus, vetor, composição, célula e método in vitro para a produção de um adenovírus ou de uma partícula semelhante a adenovírus
|
|
SG11202000247SA
(en)
|
2017-07-12 |
2020-02-27 |
Nouscom Ag |
Neoantigen vaccine composition for treatment of cancer
|
|
CA3069047A1
(en)
|
2017-07-12 |
2019-01-17 |
Nouscom Ag |
A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
|
|
CN111163799A
(zh)
|
2017-07-28 |
2020-05-15 |
扬森疫苗与预防公司 |
用于异源repRNA免疫接种的方法和组合物
|
|
GB201713163D0
(en)
*
|
2017-08-16 |
2017-09-27 |
Univ Oxford Innovation Ltd |
HPV vaccine
|
|
EP3691675A1
(en)
|
2017-08-24 |
2020-08-12 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
|
|
US11839655B2
(en)
|
2017-09-01 |
2023-12-12 |
Microvax, Llc |
Combination cancer therapy
|
|
WO2019053056A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Cell & Gene Therapies Gmbh |
RNA REPLICON FOR EXPRESSING A T CELL RECEPTOR OR ARTIFICIAL LYMPHOCYTIC T CELL RECEPTOR
|
|
AU2018358019B2
(en)
|
2017-11-03 |
2023-05-11 |
Nouscom Ag |
Vaccine T cell enhancer
|
|
US20210154277A1
(en)
|
2017-11-07 |
2021-05-27 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
MX2020007010A
(es)
|
2018-01-05 |
2020-12-10 |
Ottawa Hospital Res Inst |
Vectores modificados de orthopoxvirus.
|
|
AU2019205627B2
(en)
|
2018-01-06 |
2024-05-09 |
Emergex Vaccines Holding Limited |
MHC class I associated peptides for prevention and treatment of multiple flavi virus
|
|
AU2019207761A1
(en)
|
2018-01-11 |
2020-07-02 |
BioNTech SE |
Formulation for administration of RNA
|
|
BR112020014525A2
(pt)
|
2018-01-19 |
2020-12-08 |
Janssen Pharmaceuticals, Inc. |
Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
|
|
CN111918660A
(zh)
|
2018-01-24 |
2020-11-10 |
复诺健生物科技加拿大有限公司 |
重组病毒疫苗
|
|
CA3087044A1
(en)
|
2018-01-26 |
2019-08-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
|
|
WO2019152922A1
(en)
|
2018-02-05 |
2019-08-08 |
Nant Holdings Ip, Llc |
Calreticulin and fusion proteins
|
|
US11376290B2
(en)
|
2018-03-14 |
2022-07-05 |
Wuhan Boweid Biotechnology Co., Ltd. |
Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
|
|
US20210015878A1
(en)
|
2018-03-28 |
2021-01-21 |
Epicentrx, Inc. |
Personalized cancer vaccines
|
|
US20230149310A1
(en)
|
2018-03-30 |
2023-05-18 |
Arcturus Therapeutics, Inc. |
Lipid particles for nucleic acid delivery
|
|
TWI816603B
(zh)
|
2018-04-23 |
2023-09-21 |
美商南特細胞公司 |
新抗原表位疫苗及免疫刺激組合物及方法
|
|
GB201807932D0
(en)
|
2018-05-16 |
2018-06-27 |
Redchenko Irina |
Compositions and methods for inducing an immune response
|
|
KR20210013105A
(ko)
|
2018-05-23 |
2021-02-03 |
그릿스톤 온콜로지, 인코포레이티드 |
공유 항원
|
|
TW202000906A
(zh)
|
2018-05-23 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
免疫檢查點抑制劑共表現載體
|
|
AU2019277361A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
WO2019238023A1
(en)
*
|
2018-06-11 |
2019-12-19 |
Chineo Medical Technology Co., Ltd. |
Neoantigen vaccines and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
WO2020014539A1
(en)
|
2018-07-11 |
2020-01-16 |
Epicentrx, Inc. |
Methods and compositions for targeting cancer cells for treatment
|
|
US20210238244A1
(en)
|
2018-07-26 |
2021-08-05 |
Frame Pharmaceuticals B.V. |
Off-the-shelf cancer vaccines
|
|
GB201812647D0
(en)
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
CN116162654A
(zh)
|
2018-09-15 |
2023-05-26 |
纪念斯隆凯特琳癌症中心 |
用于癌症免疫疗法的重组痘病毒
|
|
US20210393757A1
(en)
|
2018-10-01 |
2021-12-23 |
The Wistar Institute |
Melanoma Canine Vaccine Compositions and Methods of Use Thereof
|
|
WO2020073045A1
(en)
|
2018-10-05 |
2020-04-09 |
Nantcell, Inc. |
Cd40 and cd40l combo in an adenovirus vaccine vehicle
|
|
JP2022512595A
(ja)
|
2018-10-05 |
2022-02-07 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
|
|
AU2019361280A1
(en)
|
2018-10-19 |
2021-03-11 |
Nouscom Ag |
Teleost invariant chain cancer vaccine
|
|
US20220125919A1
(en)
|
2018-11-07 |
2022-04-28 |
Gritstone Bio, Inc. |
Alphavirus neoantigen vectors and interferon inhibitors
|
|
JP2022506839A
(ja)
|
2018-11-07 |
2022-01-17 |
モデルナティエックス インコーポレイテッド |
Ｒｎａがんワクチン
|
|
JP7477888B2
(ja)
|
2018-11-15 |
2024-05-02 |
ノイスコム アーゲー |
個別化された癌ワクチンの作製のための癌変異の選択
|
|
CN113056284A
(zh)
|
2018-11-20 |
2021-06-29 |
巴法里安诺迪克有限公司 |
通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
|
|
JP2022512384A
(ja)
|
2018-12-13 |
2022-02-03 |
ロード アイランド ホスピタル |
Ａｓｐｈ発現腫瘍の成長および進行の阻害
|
|
CA3121430A1
(en)
|
2018-12-14 |
2020-06-18 |
Glaxosmithkline Biologicals Sa |
Heterologous prime boost vaccine compositions and methods
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109806390A
(zh)
|
2019-01-07 |
2019-05-28 |
康希诺生物股份公司 |
一种SamRNA疫苗及其制备方法
|
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
TW202043272A
(zh)
|
2019-01-14 |
2020-12-01 |
美商建南德克公司 |
使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法
|
|
SG11202107396RA
(en)
|
2019-01-21 |
2021-08-30 |
Sanofi Sa |
Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
EP3721899A1
(en)
|
2019-04-08 |
2020-10-14 |
China Medical University |
Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
|
|
CA3140019A1
(en)
|
2019-05-30 |
2020-12-03 |
Gritstone Bio, Inc. |
Modified adenoviruses
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|